Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?

JACC Basic Transl Sci. 2017 Aug 4;2(4):355-357. doi: 10.1016/j.jacbts.2017.07.004. eCollection 2017 Aug.

Authors

Douglas L Mann¹, Daniel P Kelly²

Affiliations

¹ Center for Cardiovascular Research, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
² Penn Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

No abstract available

Keywords: SGLT; cardiovascular disease; diabetes mellitus; empagliflozin; sodium glucose transport inhibitor.

Publication types

Editorial

Grants and funding